GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

A new study shows that using tirzepatide together with menopause hormone therapy can lead to greater weight loss in postmenopausal women who are overweight or have obesity. These findings were shared ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure. This effect happened through direct action on the heart muscle and blood ...

A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight ...

As anyone who prescribes GLP-1 therapies is surely aware, access remains a significant barrier to treatment due to lack of insurance coverage and, at times, lack of medication supply. In these ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.